Emily Behar, MS is a Research Study Coordinator at the Substance Use Research Unit at the San Francisco Department of Public Health (SFDPH) where she manages a portfolio of clinical, behavioral and implementation research studies aimed to reduce opioid-related morbidity and mortality. Emily's research focuses on improving opioid stewardship initiatives in primary care settings to support patient-centered management of pain and opioid use disorder. She has worked extensively to increase naloxone prescribing to patients on chronic opioids in San Francisco and throughout California. Emily received a Master's of Science in Medical Anthropology from the University of Pennsylvania where she focused on systemic structures of violence in vulnerable populations. Emily is currently a doctoral candidate in the Global Health Sciences Department at the University of California, San Francisco.
Phillip Coffin, M.D., M.I.A., F.A.C.P. is the Co-Principal Investigator of SHARP. He is the Director of Substance Use Research at the San Francisco Department of Public Health. He is a board certified internal medicine and infectious diseases clinician; specific foci of Dr. Coffin’s training include HIV management, buprenorphine maintenance, addiction management, toxicology, and viral hepatitis care. As Director, Dr. Coffin oversees several pharmacologic and behavioral trials that aim to reduce substance use and related risk behaviors for blood-borne virus infection. Since the early 1990s, Dr. Coffin has been involved in developing and studying services for drug users, including syringe exchange, pharmacotherapy, and overdose prevention programming.
Dr. Coffin completed his undergraduate studies at Brown University, graduate studies in international affairs at Columbia University, and obtained his medical degree at the University of California, San Francisco. He returned to Columbia University to complete his internal medicine residency, then moved to Seattle to complete his training with an infectious diseases fellowship at the University of Washington.
In addition to the intersection between substance use and HIV, Dr. Coffin’s interests include screening and linkage to care for persons with hepatitis C; opioid overdose and the distribution of naloxone; mathematical modeling of substance use and infectious diseases; and clinical care for HIV, viral hepatitis, and general infectious diseases. Dr. Coffin has an established record of clinical experience, academic service, and innovative research, and his expertise in the field is evidenced by his extensive presentation and publication record. Dr. Coffin is also credited with developing a major international conference, Preventing Heroin Overdose: Pragmatic Approaches, and establishing the first hospital-based naloxone distribution program at Columbia University Medical Center.
Jaclyn Hern, MPH is a Research Study Coordinator at the San Francisco Department of Public Health (SFDPH). She received her Masters of Public Health in Epidemiology from George Washington University in Washington, DC. Here at SFDPH, Jaclyn assists in the coordination of pharmacologic studies that aim to reduce substance use and related HIV risk behaviors. Previously, Jaclyn coordinated studies looking at antiretroviral medication adherence among HIV-infected pediatric patients and the acceptance of routine HIV screening in pediatric emergency departments at Children’s National Medical Center in Washington, DC. She has also worked on a city-wide longitudinal cohort there that aims to describe clinical outcomes and improve the care of HIV-infected individuals.
Albert Liu, MD, MPH is the Director of HIV Prevention Intervention Studies at Bridge HIV and an Assistant Clinical Professor of Medicine at UCSF. He is a board certified internist and instructs internal medicine residents in the care of underserved populations. After completing his MD at UCSF and MPH at UC Berkeley, he served as Medical Director of the Haight Ashbury Free Medical Clinic for 2 years. Dr. Liu’s research focuses on pre-exposure prophylaxis (PrEP), the use of HIV treatment medications to prevent new infections in HIV-negative individuals. He is currently the Protocol Chair of the Demo Project, a PrEP Demonstration Project in San Francisco, Miami, and Washington DC. Dr. Liu was awarded an NIH grant to develop strategies to promote PrEP adherence in real-world settings. The EPIC study (Enhancing PrEP in Communities) will explore factors that influence adherence and risk behaviors in the Demo Project and develop and test a package of online and mobile health tools to promote the uptake and adherence to PrEP in diverse settings. Dr. Liu is also directing the San Francisco effort in an international study evaluating the safety of a rectal gel – known as a microbicide – to prevent the acquisition of HIV among men who have sex with men and transgender women.
John A. Sauceda, PhD, MSc is a health psychologist by training and Assistant Professor at the Center for AIDS Prevention Studies in the Division of Prevention Science at UCSF. His research aims to improve mental health outcomes and reduce health disparities in Spanish and English-speaking Latino/a communities impacted by HIV. His NIMH-funded research projects include assessing the concept and dimensions of engagement in HIV care among Spanish and English-speaking Latinos in San Francisco, and to model the trajectories of HIV treatment outcomes as a function of depression and substance use in a national cohort of Latinos in HIV care settings. His current NIMH K01 is to develop a sequential multiple assignment randomized trial to develop an adaptive cognitive and behavioral therapy program for depression with the aid of a mobile health tool. He seeks to understand the role of Latino/a culture and Spanish language in mental health treatment utilization and HIV care and treatment management.
Susan Scheer, PhD, MPH, has over 20 years of experience in HIV research and over 12 years of experience working with HIV surveillance data and related studies. She works closely with other HIV surveillance jurisdictions nationally on capacity building & shares HIV surveillance best practices both nationally and internationally. Additionally, Dr. Scheer has developed methods for using surveillance data to monitor and evaluate HIV prevention programs and has extensive experience applying these methods and data to HIV prevention strategies.
Caitlin Turner, MPH is a Data Analyst with the Substance Use Research Unit (SURU) at the San Francisco Department of Public Health (SFDPH). Currently, she manages the Substance Use Related Death Surveillance database, conducts substance-related data analysis projects, and supports day-to-day operations of the pharmacological interventions held at SURU. Previously, she analyzed the characteristics of men who have sex with men (MSM) who were high engagers in a novel text messaging data collection platform that gathered daily information about their substance, alcohol, and study medication use. She also researched the psychosocial predictors of engagement in sexual risk behavior among trans*female youth enrolled in the SHINE study at SFDPH. As an aspiring social epidemiologist, her research interests include social determinants of health, substance use research, and the translation of findings to policy action. She received her Master of Public Health degree in Epidemiology/Biostatistics from UC Berkeley. Caitlin was also an honorary SHARP scholar in the summer of 2015 and is eager to bring that perspective to her role as a mentor.
Erin Wilson, DrPH is a research scientist at the San Francisco Department of Public Health (SFDPH) and an Assistant Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco. Dr. Wilson has been doing qualitative and mixed methods HIV prevention, care and intervention research with the trans community for almost 20 years. Dr. Wilson is currently the Principal Investigator (PI) of a 5-year NIH R01 to longitudinally study HIV risk and resilience among trans youth in the San Francisco Bay Area, and of an international prospective HIV incidence study of transwomen in 4 countries. She is also the PI for the evaluation of a Special Projects of National Significance to increase engagement and retention in HIV care among transgender women of color and among young gay and transwomen. She is also Co-PI of the first PrEP Demonstration Project for the trans community called the Stay Study. Dr. Wilson’s international experience has focused on formative research to inform behavioral surveillance studies among key populations at risk for HIV/AIDS in Mozambique, Zambia, and the Ivory Coast. She has also conducted an original research project of the HIV risk environment for transgender women in Nepal and continues to seek funding to reduce disparities in HIV risk among transgender women around the globe.